Press Releases

BioMS Medical Appoints Drug Development Expert

Dr. Tony Verco appointed Vice President of Clinical and Medical Affairs

Edmonton, Alberta, October 14, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce the appointment of Dr. Tony Verco, MBBCh, DA, to the newly-created position of Vice President of Clinical and Medical Affairs.

“With our lead MS drug, MBP8298, poised to commence a pivotal trial, we have focused on assembling a world-class clinical development team, demonstrating our ongoing commitment to the advancement this drug,” said Mr. Kevin Giese, President of BioMS Medical. “Dr. Verco, having extensive experience in all phases of clinical trials and in a variety of therapeutic areas, will be a strong addition to this team.”

In his most recent position, Dr. Verco was the Medical Director at Endpoint Research, where he was responsible for medical support and strategy for clients in a number of therapeutic areas, including multiple sclerosis. Prior to this, he was the Medical Director for AstraZeneca's Clinical Pharmacology Unit in Nottingham, UK and has been a member of numerous drug safety monitoring boards. Dr. Tony Verco earned a MBBCh degree from the University of the Witwatersrand in Johannesburg, South Africa, where he also earned his DA (Anaesthetics). He practiced clinical anaesthesia for five years before joining the pharmaceutical industry in 1996.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.